75
Participants
Start Date
September 8, 2017
Primary Completion Date
December 3, 2019
Study Completion Date
June 7, 2021
Gemcitabine
Gemcitabine 1000 mg/m2 IV
Cisplatin
Cisplatin 25 mg/m2 IV
Ipilimumab
Ipilimumab 1 mg/kg IV
Nivolumab
Nivolumab 360 mg or 240 mg IV
University of Pennsylvania, Philadelphia
Emory University, Atlanta
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Wisconsin, Madison
Northwestern University, Chicago
University of Texas Southwestern Medical Center, Dallas
University of Washington, Seattle
University of Michigan Rogel Cancer Center
OTHER